In Turkey, the acute ischemic stroke drugs market is witnessing robust expansion, projected to reach approximately USD 121 million in 2025, with a notable CAGR of around 9.1 %, underpinned by the country’s rapid improvements in healthcare infrastructure, rising public and physician awareness, and targeted government initiatives aimed at enhancing stroke care accessA key growth driver is the increasing prevalence of lifestyle-related risk factors such as hypertension, diabetes, and obesity, especially among an aging population; these factors contribute to rising incidence of ischemic stroke and intensify demand for effective drug therapies The surge in chronic disease burden creates urgency for timely reperfusion treatments such as tissue plasminogen activator (tPA) therapies and secondary prevention through anticoagulant and antiplatelet medications.
TABLE - Turkey Acute Ischemic Stroke Drugs Market Size & Forecast By Drug Class 2021-2033
Drug Class | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Thrombolytics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Anticoagulant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Antiplatelet | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Neuroprotective Agent | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis